PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
| Autor: | Yan-Nan Li, Tong Zhang, Cheng-Hao Jin, Hui Xue, Guang-Ze Mou, Wan-Ting Xu, Wen-Bo Zuo, Tian-Zhu Li, Ying-Hua Luo, Yu Zhang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
PD-L1 Cancer Research medicine.medical_specialty Immune checkpoint inhibitors medicine.medical_treatment Programmed Cell Death 1 Receptor mechanism Review Antibodies Monoclonal Humanized lcsh:RC254-282 B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Combined treatment Antineoplastic Agents Immunological Internal medicine Neoplasms PD-1 medicine Animals Humans Neoplasm Metastasis anti-tumor Clinical treatment Immune Checkpoint Inhibitors 030304 developmental biology 0303 health sciences Chemotherapy biology business.industry Immunotherapy lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Combined Modality Therapy Cancer treatment Radiation therapy Nivolumab 030220 oncology & carcinogenesis biology.protein immunotherapy business |
| Zdroj: | Technology in Cancer Research & Treatment Technology in Cancer Research & Treatment, Vol 20 (2021) |
| ISSN: | 1533-0338 |
| Popis: | Recently, immunotherapy has become the fourth pillar of cancer treatment in addition to surgery therapy, chemotherapy, and radiation therapy. The inhibitors of programed cell death protein 1 (PD-1) and its ligand PD-L1 are the new stars in immunotherapy, as they can overcome tumor immunosuppression. However, the efficacy of PD-1 inhibitors still needs to be further developed for clinical treatment. Therefore, research into treatment with anti-PD-1 drugs has emerged as a new development field. This review provides novel insights into the role and mechanism of PD-1 combination anti-tumor therapy, thereby promoting its clinical application in anti-tumor immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|